Title X Grantees and Clinics Affected by the Trump Administration’s Funding Freeze
This data note looks at the Title X grantees and clinics affected by the Trump Administration's recent funding freeze.
View the Latest: Family Planning
Filter
-
-
Major Federal and State Funding Cuts Facing Planned Parenthood
Issue BriefThis issue brief presents data from the most recent tracking poll asking if people have ever visited a Planned Parenthood clinic for health care services and looks at the funding cuts Planned Parenthood is currently facing including Medicaid, Title X, and Teen Pregnancy Prevention funds.
-
Rebuilding the Title X Network Under the Biden Administration
Issue BriefThis issue brief examines what has happened to the Title X network under the Biden Administration regulations, including the number of clinics that have returned to the network, new funding, and how state policies that prohibit pregnancy options counseling that includes abortion and referrals may impact grantees' participation in the Title X program.
-
Medicaid Reimbursement Policies for Immediate Postpartum Long Acting Reversible Contraceptives (LARCs)
State Health Facts Indicator -
Will Trump’s Announcement Expand Access to IVF?
Policy WatchThe White House announcement focused on reducing the cost of some IVF drugs and clarifying options for employers to offer standalone fertility benefits for their employees and their dependents. This policy watch examines some key takeaways about the Trump IVF plan.
-
KFF Health Tracking Poll March 2024: Abortion in the 2024 Election and Beyond
FeatureThis poll finds 1 in 8 voters say abortion is the most important issue to their vote. They are younger, lean Democratic, and generally want abortion to be legal in all or most cases. The poll also gauges the public's views on abortion-related policies, including a national 16-week abortion ban and allowing abortion for pregnancy-related emergencies.
-
KFF Examines Key Considerations for the Implementation of Insurance Coverage for Over-the-Counter Contraceptives
News ReleaseWith federal regulators seeking public input on the potential benefits, costs, and implementation considerations of requiring private health insurance plans to cover over-the-counter preventive products without a prescription, a new KFF post explores the issues relevant to covering over-the-counter contraceptives. These contraceptives include Opill, the first daily oral contraceptive pill to receive FDA approval for over-the-counter availability. The analysis draws on the lessons learned from KFF staff interviews with more than 80 key players nationally…
-
Women’s Views on Whether Contraception Mandate Should Apply to For-Profit Companies Whose Owners Object
FeatureWomen’s Views on Whether Contraception Mandate Should Apply to For-Profit Companies Whose Owners Object Download
-
The Trump Administration’s Latest Expansion of the Mexico City Policy: A Funding Analysis
Issue BriefThis analysis assesses the potential reach of the latest expansion of the Mexico City Policy, which is now part of the Promoting Human Flourishing in Foreign Assistance (PHFFA) Policy.
-
Intrauterine Devices (IUDs): Access and Coverage in the U.S.
Fact SheetIntrauterine devices (IUDs), along with implants, are known as long-acting reversible contraception (LARCs) because they can be used to prevent pregnancy for several years. This fact sheet reviews FDA-approved IUDs, as well as use, availability, and key issues in insurance coverage and financing of IUDs in the U.S.